Arrowhead Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARWR research report →
Companyarrowheadpharma.com
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.
- CEO
- Christopher R. Anzalone
- IPO
- 1993
- Employees
- 609
- HQ
- Pasadena, CA, US
Price Chart
Valuation
- Market Cap
- $10.87B
- P/E
- -36.51
- P/S
- 17.47
- P/B
- 17.89
- EV/EBITDA
- -74.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.98%
- Op Margin
- -35.67%
- Net Margin
- -48.38%
- ROE
- -55.45%
- ROIC
- -10.98%
Growth & Income
- Revenue
- $829.45M · 23258.15%
- Net Income
- $-1,631,000 · 99.73%
- EPS
- $-0.01 · 99.76%
- Op Income
- $98.35M
- FCF YoY
- 125.96%
Performance & Tape
- 52W High
- $82.26
- 52W Low
- $14.30
- 50D MA
- $67.00
- 200D MA
- $52.21
- Beta
- 1.29
- Avg Volume
- 2.10M
Get TickerSpark's AI analysis on ARWR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Lu Hongbo | sell | 2,970 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 3,208 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 1,157 |
| Apr 22, 26 | Apel Daniel Joseph | sell | 8,730 |
| Apr 23, 26 | Hamilton James C | sell | 10,000 |
| Mar 5, 26 | Hamilton James C | sell | 10,000 |
| Jan 6, 26 | Hamilton James C | other | 75,000 |
| Jan 6, 26 | Apel Daniel Joseph | other | 75,000 |
| Jan 6, 26 | O'Brien Patrick | other | 75,000 |
| Jan 6, 26 | O'Brien Patrick | other | 540 |
Our ARWR Coverage
We haven't published any research on ARWR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARWR Report →